Holly Windham B., General Counsel and Chief Compliance Officer of Cellebrite DI Ltd., filed a Form 144 notice on November 10, 2026, proposing to sell 11,986 ordinary shares on approximately November 17, 2026, through Morgan Stanley Smith Barney LLC.

Key Highlights

  • Seller and role: Holly Windham B., General Counsel and Chief Compliance Officer of Cellebrite DI Ltd.
  • Shares proposed for sale: 11,986 ordinary shares, par value NIS 0.00001, with an aggregate market value of $152,222.20 according to the filing.
  • Source of shares: Restricted Share Units that vested on November 5, 2026, under an issuer S-8 registered plan, acquired as employee compensation.
  • Approximate sale date: November 17, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services in New York.
  • Purpose of sale: The filing states the sale is pursuant to "a mandatory, non-discretionary, sell-to-cover arrangement for the purposes of satisfying income tax liabilities incurred upon vesting of restricted share unit awards only."
  • Shares outstanding: 251,341,060 ordinary shares outstanding at the time of notice, according to the filing.
  • Prior sales: No securities of the issuer were reported as sold during the past three months by the reporting person.

Cellebrite DI Ltd. General Counsel Proposes Rule 144 Sale to Cover RSU Tax Obligations

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 10, 2026, Holly Windham B., who serves as General Counsel and Chief Compliance Officer of Cellebrite DI Ltd. (NASDAQ:CLBT), intends to sell 11,986 ordinary shares of the company. The filing identifies Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as the named broker for the proposed transaction.

The shares proposed for sale originated from Restricted Share Units that vested on November 5, 2026, under an issuer S-8 registered plan, with the nature of payment described as employee compensation. The aggregate market value of the shares to be sold is listed as $152,222.20 in the filing. The reporting person noted no sales of Cellebrite securities in the three months preceding the notice date.

The filing includes a remark stating that the reporting person "intends to sell securities reported herein on 11/17/2026 pursuant to a mandatory, non-discretionary, sell-to-cover arrangement for the purposes of satisfying income tax liabilities incurred upon vesting of restricted share unit awards only." The total shares outstanding are reported as 251,341,060.

What Was Disclosed

Cellebrite DI Ltd.'s General Counsel and Chief Compliance Officer, Holly Windham B., filed a Form 144 notice proposing to sell 11,986 RSU-vested ordinary shares on approximately November 17, 2026, in a mandatory sell-to-cover arrangement to satisfy tax obligations arising from the vesting event.